Breast CancerPhase 2STARTRK-2NCT02568267

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

A Phase 2 study testing Entrectinib in people with Breast Cancer and Cholangiocarcinoma, run by Hoffmann-La Roche at 120 sites in 16 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer
What is being tested?: Entrectinib
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 534 participants
Where: 120 sitesin 16 countries
Study dates: 19 Nov 2015to 30 Jun 2027
Phase: Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment
Measurable or evaluable disease
Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed
Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements)
Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.

Show all 13Show fewer

At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy
At least 4 weeks must have elapsed since completion of antibody-directed therapy
Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of 4 weeks
Adequate organ function as defined per protocol
Ability to swallow entrectinib intact
Other protocol specified criteria

Who cannot join

Current participation in another therapeutic clinical trial
Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements
Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
History of other previous cancer that would interfere with the determination of safety or efficacy
Familial or personal history of congenital bone disorders, or bone metabolism alterations
Incomplete recovery from any surgery

Show all 14Show fewer

History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤50% observed during screening for the study
History of non-pharmacologically induced prolonged QTc interval
History of additional risk factors for torsades de pointes
Peripheral neuropathy Grade ≥ 2
Known active infections
Active gastrointestinal disease or other malabsorption syndromes
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
Other protocol specified criteria

Trial locations and contacts

120 sites in 16 countries.

Country

City, postcode or hospital

120 sites in 16 countries

United States48 sites

University Cancer & Blood Center, LLC
Athens, Georgia, 30607
Winship Cancer Institute
Atlanta, Georgia, 30322
University of Colorado Cancer Center
Aurora, Colorado, 80045
Weinberg Cancer Institution at Franklin Square
Baltimore, Maryland, 21237
Massachusetts General Hosp CAR
Boston, Massachusetts, 02114
Massachusetts General Hospital
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, 28204
Levine Cancer Institute
Charlotte, North Carolina, 28204
Northwestern University
Chicago, Illinois, 60611
Ohio State University
Columbus, Ohio, 43210
OSU, James Cancer Hospital
Columbus, Ohio, 43210
Mary Crowley Medical Research Center
Dallas, Texas, 75230
Karmanos Cancer Center
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
City of Hope Cancer Center
Duarte, California, 91010
City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services
Duarte, California, 91010
Duke Cancer Institute
Durham, North Carolina, 27710
North Shore Hem Onc Associates
East Setauket, New York, 11733
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031
Scripps Clinic
La Jolla, California, 92037
University of California San Diego Moores Cancer Center
La Jolla, California, 92093
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
Las Vegas, Nevada, 89169
Southern California Kaiser Permanente
Los Angeles, California, 90027
Regents of the University of Minnesota
Minneapolis, Minnesota, 55455
Yale University
New Haven, Connecticut, 6519
Memorial Sloan Kettering Cancer Center
New York, New York, 10022
Southeastern Regional Medical Center, Inc.
Newnan, Georgia, 30265
Virginia Oncology Associates - Hampton
Norfolk, Virginia, 23502
Univ Of California Irvine College Of Medicine
Orange, California, 92868
Advocate Medical Group - Park Ridge, Luther Lane - Oncology
Park Ridge, Illinois, 60068
Dignity Health St Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Mayo Clinic
Phoenix, Arizona, 85054
Oregon Health & Science University
Portland, Oregon, 97239-3098
Oregon Health & Science Univ
Portland, Oregon, 97239
UCSF Mount Zion Medical Ctr
San Francisco, California, 94115
UCSF Mission Bay
San Francisco, California, 94158
Sarcoma Oncology Center
Santa Monica, California, 90403
Sarcoma Oncology Research Center LLC
Santa Monica, California, 90403
Florida Cancer Specialists - Sarasota
Sarasota, Florida, 34232
Washington University
St Louis, Missouri, 63128
H. Lee Moffitt Cancer Center and Research Inst.
Tampa, Florida, 33612-9497
Moffitt Cancer Center
Tampa, Florida, 33612-9497
Baylor Scott & White Health
Temple, Texas, 76508
Cancer Treatment Centers of America
Tulsa, Oklahoma, 74133
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, 20007
Midwestern Regional Medical Center
Zion, Illinois, 60099

Other trials in United States

China9 sites

Beijing Cancer Hospital
Beijing, 100142
Sichuan Cancer Hospital
Chengdu, Sichuan, 610041
Cancer Center of Guangzhou Medical University
Guangzhou, 528400
Zhejiang Cancer Hospital
Hangzhou, 310022
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081
Shanghai chest hospital
Shanghai, 200030
Fudan University Shanghai Cancer Center
Shanghai, 200120
Shenzhen People's Hospital
Shenzhen, 510852
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430023

Other trials in China

France9 sites

Institut de Cancerologie de l Ouest
Angers, 49055
Institut Bergonie
Bordeaux, 33076
Centre Leon Berard
Lyon, 69373
Hôpital de la Timone
Marseille, 13385
Hôpital Nord - AP-HM Marseille#
Marseille, 13915
Institut de Recherche en Cancérologie de Montpellier
Montpellier, 34090
Institut Curie
Paris, 75005
Institut Claudius Regaud
Toulouse, 31059
Institut Gustave Roussy
Villejuif, 94805

Other trials in France

Japan9 sites

Aichi Cancer Center Hospital
Aichi, 464-8681
National Cancer Center Hospital
Chūō, 104-0045
Hyogo Cancer Center, Dept of Respiratory Medicine
Hyōgo, 673-8558
NHO Shikoku Cancer Center
Matsuyama, 791-0280
Miyagi Cancer Center
Miyagi, 981-1293
Niigata Cancer Center Hospital
Niigata, 951-8566
Osaka City General Hospital
Osaka, 534-0021
Kindai University Hospital
Osaka, 589-8511
Shizuoka Cancer Center
Shizuoka, 411-8777

Other trials in Japan

Spain8 sites

Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035
Centro Nacional de Investigaciones Oncológicas(CNIO)
Fuenlabrada, Madrid, 28942
Hospital Universitario Ramon y Cajal
Madrid, 28034
Hospital Universitario Clínico San Carlos
Madrid, 28040
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital Universitario La Paz
Madrid, 28046
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010
Hospital Universitario Virgen del Rocio
Seville, 41013

Other trials in Spain

Italy7 sites

Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
Milan, Lombardy, 20162
Seconda Università degli Studi di Napoli
Naples, Campania, 80131
IOV - Istituto Oncologico Veneto - IRCCS
Padova, Veneto, 35128
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
Perugia, Umbria, 6132
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, 56126
Università Campus Bio-Medico di Roma
Rome, Lazio, 128

Other trials in Italy

Australia4 sites

Flinders Medical Centre
Bedford Park, South Australia, 5042
Austin Health
Heidelberg, Victoria, 3084
Liverpool Hospital
Liverpool, New South Wales, 2170
Newcastle Private Hospital
Newcastle, New South Wales, 2305

Other trials in Australia

Germany4 sites

Evang. Lungenklinik Berlin Klinik für Pneumologie
Berlin, 13125
Universitaetsklinikum Koeln
Cologne, 50937
Universitaetsmedizin Goettingen
Göttingen, 37075
NCT Uniklinikum Heidelberg
Heidelberg, 69120

Other trials in Germany

Hong Kong4 sites

Princess Margaret Hospital
Hong Kong
The University of Hong Kong
Hong Kong
Queen Elizabeth Hospital
Kowloon
The Chinese University of Hong Kong
Shatin, 123456

Other trials in Hong Kong

Poland4 sites

Uniwersyteckie Centrum Kliniczne
Gda?sk, 80-214
Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
Gliwice, 44-101
Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego
Późna, 60-569
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego
Warsaw, 02-781

Other trials in Poland

South Korea4 sites

Seoul National University Hospital
Seoul, 03080
Asan Medical Center.
Seoul, 05505
Samsung Medical Center
Seoul, 06351
Severance Hospital, Yonsei University Health System
Seoul, 120-752

Other trials in South Korea

Taiwan3 sites

National Cheng Kung University Hospital
Tainan, 70457
National Taiwan University Hospital
Taipei, 00100
Taipei Veterans General Hospital
Taipei, 11217

Other trials in Taiwan

United Kingdom3 sites

Addenbrookes Hospital
Cambridge, CB2 0QQ
Sarah Cannon Research Institute
London, W1G 6AD
The Christie
Manchester, M20 4BX

Other trials in United Kingdom

Singapore2 sites

National University Hospital
Singapore, 119228
National Cancer Centre Singapore
Singapore, 168583

Other trials in Singapore

Belgium1 site

Pharmacy
Edegem, 2650

Other trials in Belgium

Netherlands1 site

Leids Universitair Medisch Centrum
Leiden, 2333 ZA

Other trials in Netherlands

About this study

Official title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma
Being tested: Entrectinib
Keywords: Entrectinib, RXDX-101, TrkA, TrkB, TrkC, NTRK1, NTRK2, NTRK3, ROS1, ALK, Trk Fusions, NTRK Gene Rearrangements, ROS1 Fusions, ROS1 Gene Rearrangements, ALK Fusions, ALK Gene Rearrangements, Basket study, Non-small cell lung cancer, Colorectal cancer, Salivary gland cancers
Medical subject headings: Breast Neoplasms, Cholangiocarcinoma, Colorectal Neoplasms, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Carcinoma, Non-Small-Cell Lung

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

EntrectinibDrug
Also called RXDX-101
TrkA/B/C, ROS1, and ALK inhibitor

Study groups in NCT02568267
Study group	Role	What they receive
NTRK1/2/3-rearranged NSCLC	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
ROS1-rearranged NSCLC	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
ALK- or ROS1-rearranged NSCLC	Experimental	with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.) Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
NTRK/1/2/3-rearranged mCRC	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
ROS1-rearranged mCRC	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
ALK-rearranged mCRC	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
NTRK1/2/3-rearranged other solid tumor	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
ROS1-rearranged other solid tumor	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib
ALK-rearranged other solid tumor	Experimental	Oral entrectinib (RXDX-101) Receives: Drug: Entrectinib

What is being measured

The primary outcome is the main question the study is designed to answer.

Objective Response Rate
Assessed by blinded independent central review (BICR) using RECIST v1.1
Measured: Approximately 24 months

Secondary outcomes (12)

Duration of Response
Assessed by blinded independent central review (BICR) using RECIST v1.1
Measured: Approximately 24 months
Time to Response
Assessed by blinded independent central review (BICR) using RECIST v1.1
Measured: Approximately 24 months
Clinical Benefit Rate
Assessed by blinded independent central review (BICR) using RECIST v1.1
Measured: Approximately 24 months
Intracranial Tumor Response
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable
Measured: Approximately 24 months
CNS Progression-free Survival
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable
Measured: Approximately 24 months
Progression-free Survival
Assessed by Kaplan-Meier method
Measured: Approximately 30 months
Overall Survival
Assessed by Kaplan-Meier method
Measured: Approximately 36 months
Population PK
Assessed by Kaplan-Meier method
Measured: Approximately 24 months
Adverse Events
Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE
Measured: Approximately 36 months
Quality of Life
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively
Measured: Approximately 24 months
Bone Growth and Bone Mineral Density
Assessed with DHA scans
Measured: Approximately 30 months
Bone Biomarkers
Measured by blood
Measured: Approximately 30 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

19 Nov 201530 Jun 2027

First posted5 Oct 2015 (estimated)
Study start19 Nov 2015
Primary completion30 Jun 2027 (estimated)
Study completion30 Jun 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (11)Papers the sponsor has linked to this study.
Other trials for Breast CancerStudies of the same condition, open and under way.
More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 534 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02568267
Sponsor's protocol ID: RXDX-101-02
Other IDs: 2015-003385-84, GO40782, 2015
Acronym: STARTRK-2
Status last verified: Aug 2026
First submitted: 2 Oct 2015
Last updated: 25 Aug 2026
Results posted: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Expanded access: Available

Publications

Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein M. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 May;23(5):169-191. doi: 10.6004/jnccn.2025.0022.
PubMed 40341199
Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
PubMed 40086048
Yu Y, Fan Y, Dong X, Li J, Yu Y, Zhao J, Tao S, Chen Y, Chen M, Liu Y, Xu J, Zhu Q, Hu X, Lu S. Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. Lung Cancer. 2024 Dec;198:108018. doi: 10.1016/j.lungcan.2024.108018. Epub 2024 Nov 10.
PubMed 39549678
Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib. JCO Precis Oncol. 2024 Jun;8:e2300721. doi: 10.1200/PO.23.00721.
PubMed 38848521
Yokota T, Yukino H, Doi M, Ohori H. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series. Head Neck. 2023 May;45(5):E10-E15. doi: 10.1002/hed.27346. Epub 2023 Mar 16.
PubMed 36924196
Sullivan WG, Hatswell AJ. Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO Open. 2021 Dec;6(6):100282. doi: 10.1016/j.esmoop.2021.100282. Epub 2021 Oct 28. No abstract available.
PubMed 34924145
Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24.
PubMed 34427452
Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
PubMed 33646820
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
PubMed 31838015
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
PubMed 31838007
Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.
PubMed 29118225